Search results
Results from the WOW.Com Content Network
Hypermagnesemia is an electrolyte disorder in which there is a high level of magnesium in the blood. [3] Symptoms include weakness, confusion, decreased breathing rate, and decreased reflexes. Hypermagnesemia can greatly increase the chances of adverse cardiovascular events. [1] [3] Complications may include low blood pressure and cardiac ...
Hypermagnesemia typically occurs in individuals with abnormal kidney function. This imbalance can also occur with use of antacids or laxatives that contain magnesium. Iatrogenic cases of hypermagnesemia can be prevented by avoiding magnesium-containing medications. [citation needed]
Deficiency of magnesium can cause tiredness, generalized weakness, muscle cramps, abnormal heart rhythms, increased irritability of the nervous system with tremors, paresthesias, palpitations, low potassium levels in the blood, hypoparathyroidism which might result in low calcium levels in the blood, chondrocalcinosis, spasticity and tetany, migraines, epileptic seizures, [7] basal ganglia ...
Young adults are more likely than either younger children or older adults to be diagnosed with certain cancers, such as Hodgkin lymphoma, testicular cancer, and some types of sarcomas. In adolescents and young adults 15 to 24 years old, lymphoma , testicular cancer, and thyroid cancer are the most common types, while among 25- to 39-year-olds ...
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
Childhood AML treatment usually consists higher dose chemotherapy given over a shorter period of time compared to ALL treatment. Due to this shorter and more intense treatment, side effects are also more intense. These children are therefore treated in treatment centers or hospitals where they will stay for longer period of their treatment.
Secondary hyperaldosteronism (also hyperreninism, or hyperreninemic hyperaldosteronism) is due to overactivity of the renin–angiotensin–aldosterone system (RAAS).. The causes of secondary hyperaldosteronism are accessory renal veins, fibromuscular dysplasia, reninoma, renal tubular acidosis, nutcracker syndrome, ectopic tumors, massive ascites, left ventricular failure, and cor pulmonale.
[1] [3] The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive. [3] In 2015, AML affected about one million people, and resulted in 147,000 deaths globally. [4] [5] It most commonly occurs in older adults. [2] Males are affected more often than females. [2]